Cost-effectiveness of various maintenance therapies based on mutation status following first-line treatment of primary epithelial ovarian cancer in the United States

被引：0
|
作者：
Penn, Courtney Alexis [1 ]
Wong, Melissa Spring [2 ]
Walsh, Christine [2 ]
机构：
[1] Cedars Sinai Med Ctr, Womens Canc Program, Los Angeles, CA 90048 USA
[2] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA
来源：
GYNECOLOGIC ONCOLOGY | 2020年 / 159卷 / 02期
关键词：
D O I：
10.1016/j.ygyno.2020.07.050
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
18
引用
收藏
页码：E14 / E14
页数：1
相关论文
共 50 条
  • [1] Cost-effectiveness of various maintenance therapies based on mutation status following first-line treatment of primary epithelial ovarian cancer in the United States.
    Penn, Courtney
    Wong, Melissa
    Walsh, Christine S.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [2] Cost-effectiveness of Maintenance Therapy Based on Molecular Classification Following Treatment of Primary Epithelial Ovarian Cancer in the United States
    Penn, Courtney A.
    Wong, Melissa S.
    Walsh, Christine S.
    JAMA NETWORK OPEN, 2020, 3 (12)
  • [3] COST-EFFECTIVENESS OF CETUXIMAB AS FIRST-LINE TREATMENT FOR METASTATIC COLORECTAL CANCER IN THE UNITED STATES
    Ortendahl, J. D.
    Bentley, T. G.
    Anene, A. M.
    Purdum, A. G.
    Bolinder, B.
    VALUE IN HEALTH, 2014, 17 (03) : A86 - A86
  • [4] Cost-Effectiveness of Cetuximab as First-line Treatment for Metastatic Colorectal Cancer in the United States
    Shankaran, Veena
    Ortendahl, Jesse D.
    Purdum, Anna G.
    Bolinder, Bjorn
    Anene, Ayanna M.
    Sun, Gordon H.
    Bentley, Tanya G. K.
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2018, 41 (01): : 65 - 72
  • [5] Cost-effectiveness of maintenance therapy after first-line treatment in metastatic colorectal cancer
    Giuliani, Jacopo
    Mantoan, Beatrice
    Bonetti, Andrea
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2022, 28 (01) : 194 - 198
  • [6] Cost-Effectiveness of Pembrolizumab as First-Line Treatment in Patients with Persistent, Recurrent, or Metastatic Cervical Cancer in the United States
    Monk, Bradley J.
    van Mens, Sophie
    Hale, Oliver
    Boer, Jennifer
    van Hees, Frank
    Swami, Shilpi
    Muston, Dominic
    Tekin, Cumhur
    Keefe, Steve
    Monberg, Matthew
    ONCOLOGY AND THERAPY, 2025, 13 (01) : 85 - 98
  • [7] COST-EFFECTIVENESS OF PEMBROLIZUMAB FOR FIRST-LINE TREATMENT IN PATIENTS WITH PERSISTENT, RECURRENT, OR METASTATIC CERVICAL CANCER IN THE UNITED STATES
    Monk, Bradley
    Boer, Jennifer
    Van Hees, Frank
    Van Mens, Sophie
    Swami, Shilpi
    Muston, Dominic
    Tekin, Cumhur
    Keefe, Steve
    Monberg, Matthew
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2022, 32 : A38 - A38
  • [8] Olaparib plus bevacizumab as a first-line maintenance treatment for patients with advanced ovarian cancer by molecular status: an updated PAOLA-1 based cost-effectiveness analysis
    Zhu, Youwen
    Yang, Qiuping
    Liu, Kun
    Cao, Hui
    Zhu, Hong
    JOURNAL OF GYNECOLOGIC ONCOLOGY, 2024, 35 (01)
  • [9] Olaparib in combination with bevacizumab compared to bevacizumab monotherapy for the first-line maintenance treatment of advanced ovarian cancer: a cost-effectiveness analysis
    Fan, Lin
    Muston, Dominic
    Elsea, David
    El Moustaid, Fadoua
    Mihai, Adela
    Simmons, Daniel
    McLaurin, Kimmie
    Monberg, Matthew
    GYNECOLOGIC ONCOLOGY, 2021, 162 : S216 - S217
  • [10] Cost-effectiveness of pembrolizumab plus platinum and fluoropyrimidine-based chemotherapy as first-line treatment of advanced esophageal cancer in the United States
    Qu, T.
    Zhong, Y.
    Zhang, S.
    Meng, Y.
    Joo, S.
    Shah, S.
    ANNALS OF ONCOLOGY, 2021, 32 : S1059 - S1060
12345